|
1
|
Ottaviani G, Robert RS, Huh WW, Palla S
and Jaffe N: Sociooccupational and physical outcomes more than 20
years after the diagnosis of osteosarcoma in children and
adolescents: Limb salvage versus amputation. Cancer. 119:3727–3736.
2013.PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
3
|
Ozaki T, Flege S, Kevric M, Lindner N,
Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik
M, Berdel WE, et al: Osteosarcoma of the pelvis: Experience of the
Cooperative Osteosarcoma Study Group. J Clin Oncol. 21:334–341.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chou AJ, Kleinerman ES, Krailo MD, Chen Z,
Betcher DL, Healey JH, Conrad EU III, Nieder ML, Weiner MA, Wells
RJ, et al Children’s Oncology Group: Addition of muramyl tripeptide
to chemotherapy for patients with newly diagnosed metastatic
osteosarcoma: A report from the Children’s Oncology Group. Cancer.
115:5339–5348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grignani G, Palmerini E, Dileo P, Asaftei
SD, D’Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F,
Casali PG, et al: A phase II trial of sorafenib in relapsed and
unresectable high-grade osteosarcoma after failure of standard
multimodal therapy: An Italian Sarcoma Group study. Ann Oncol.
23:508–516. 2012. View Article : Google Scholar
|
|
6
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar
|
|
7
|
Lu CD, Altieri DC and Tanigawa N:
Expression of a novel anti-apoptosis gene, survivin, correlated
with tumor cell apoptosis and p53 accumulation in gastric
carcinomas. Cancer Res. 58:1808–1812. 1998.PubMed/NCBI
|
|
8
|
Kawasaki H, Altieri DC, Lu CD, Toyoda M,
Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin
predicts shorter survival rates in colorectal cancer. Cancer Res.
58:5071–5074. 1998.PubMed/NCBI
|
|
9
|
Monzó M, Rosell R, Felip E, Astudillo J,
Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A and Abad A: A
novel anti-apoptosis gene: Re-expression of survivin messenger RNA
as a prognosis marker in non-small-cell lung cancers. J Clin Oncol.
17:2100–2104. 1999.PubMed/NCBI
|
|
10
|
Tanaka K, Iwamoto S, Gon G, Nohara T,
Iwamoto M and Tanigawa N: Expression of survivin and its
relationship to loss of apoptosis in breast carcinomas. Clin Cancer
Res. 6:127–134. 2000.PubMed/NCBI
|
|
11
|
Liggins C, Orlicky DJ, Bloomquist LA and
Gianani R: Developmentally regulated expression of Survivin in
human pancreatic islets. Pediatr Dev Pathol. 6:392–397. 2003.
View Article : Google Scholar
|
|
12
|
Xing J, Jia CR, Wang Y, Guo J and Cai Y:
Effect of shRNA targeting survivin on ovarian cancer. J Cancer Res
Clin Oncol. 138:1221–1229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krajewska M, Krajewski S, Banares S, Huang
X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A,
Peehl D, et al: Elevated expression of inhibitor of apoptosis
proteins in prostate cancer. Clin Cancer Res. 9:4914–4925.
2003.PubMed/NCBI
|
|
14
|
McKenzie JA and Grossman D: Role of the
apoptotic and mitotic regulator survivin in melanoma. Anticancer
Res. 32:397–404. 2012.PubMed/NCBI
|
|
15
|
Dohi T, Okada K, Xia F, Wilford CE, Samuel
T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An
IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wheatley SP and McNeish IA: Survivin: A
protein with dual roles in mitosis and apoptosis. Int Rev Cytol.
247:35–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tulu US, Fagerstrom C, Ferenz NP and
Wadsworth P: Molecular requirements for kinetochore-associated
microtubule formation in mammalian cells. Curr Biol. 16:536–541.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sampath SC, Ohi R, Leismann O, Salic A,
Pozniakovski A and Funabiki H: The chromosomal passenger complex is
required for chromatin-induced microtubule stabilization and
spindle assembly. Cell. 118:187–202. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I,
Matsuhisa A, et al: YM155, a novel small-molecule survivin
suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res.
67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawano H, Shakushiro K, Nakata M, Kita A,
Maeda A, Watanabe S, Sako K and Oku N: Antitumor efficacy and
biodistribution of liposomal sepantronium bromide (YM155), a novel
small-molecule survivin suppressant. Eur J Pharm Biopharm.
88:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M,
et al: Broad spectrum and potent antitumor activities of YM155, a
novel small-molecule survivin suppressant, in a wide variety of
human cancer cell lines and xenograft models. Cancer Sci.
102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Minematsu T, Iwai M, Sugimoto K, Shirai N,
Nakahara T, Usui T and Kamimura H: Carrier-mediated uptake of
1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium
bromide (YM155 monobromide), a novel small-molecule survivin
suppressant, into human solid tumor and lymphoma cells. Drug Metab
Dispos. 37:619–628. 2009. View Article : Google Scholar
|
|
23
|
Kita A, Nakahara T, Yamanaka K, Nakano K,
Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N and Sasamata M:
Antitumor effects of YM155, a novel survivin suppressant, against
human aggressive non-Hodgkin lymphoma. Leuk Res. 35:787–792. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tolcher AW, Quinn DI, Ferrari A, Ahmann F,
Giaccone G, Drake T, Keating A and de Bono JS: A phase II study of
YM155, a novel small-molecule suppressor of survivin, in
castration-resistant taxane-pretreated prostate cancer. Ann Oncol.
4:968–973. 2012. View Article : Google Scholar
|
|
25
|
Zhang K, Li Y, Liu W, Gao X and Zhang K:
Silencing survivin expression inhibits the tumor growth of
non-small-cell lung cancer cells in vitro and in vivo. Mol Med Rep.
11:639–644. 2015.
|
|
26
|
Giaccone G, Zatloukal P, Roubec J, Floor
K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and
Shamsili S: Multicenter phase II trial of YM155, a small-molecule
suppressor of survivin, in patients with advanced, refractory,
non-small-cell lung cancer. J Clin Oncol. 27:4481–4486. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lewis KD, Samlowski W, Ward J, Catlett J,
Cranmer L, Kirkwood J, Lawson D, Whitman E and Gonzalez R: A
multi-center phase II evaluation of the small molecule survivin
suppressor YM155 in patients with unresectable stage III or IV
melanoma. Invest New Drugs. 29:161–166. 2011. View Article : Google Scholar
|
|
28
|
Yang Q, Zhang S, Kang M, Dong R and Zhao
J: Synergistic growth inhibition by sorafenib and cisplatin in
human osteosarcoma cells. Oncol Rep. 33:2537–2544. 2015.PubMed/NCBI
|
|
29
|
Follo MY, Manzoli L, Poli A, McCubrey JA
and Cocco L: PLC and PI3K/Akt/mTOR signalling in disease and
cancer. Adv Biol Regul. 57:10–16. 2015. View Article : Google Scholar
|
|
30
|
Hideshima T, Catley L, Raje N, Chauhan D,
Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, et al:
Inhibition of Akt induces significant downregulation of survivin
and cytotoxicity in human multiple myeloma cells. Br J Haematol.
138:783–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siddiqa A, Long LM, Li L, Marciniak RA and
Kazhdan I: Expression of HER-2 in MCF-7 breast cancer cells
modulates anti-apoptotic proteins Survivin and Bcl-2 via the
extracellular signal-related kinase (ERK) and phosphoinositide-3
kinase (PI3K) signalling pathways. BMC Cancer. 8:1292008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Osaka E, Suzuki T, Osaka S, Yoshida Y,
Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, et al:
Survivin as a prognostic factor for osteosarcoma patients. Acta
Histochem Cytochem. 39:95–100. 2006. View Article : Google Scholar
|
|
33
|
Trieb K, Lehner R, Stulnig T, Sulzbacher I
and Shroyer KR: Survivin expression in human osteosarcoma is a
marker for survival. Eur J Surg Oncol. 29:379–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shoeneman JK, Ehrhart EJ III, Eickhoff JC,
Charles JB, Powers BE and Thamm DH: Expression and function of
survivin in canine osteosarcoma. Cancer Res. 72:249–259. 2012.
View Article : Google Scholar
|
|
35
|
Zou J, Gan M, Mao N, Zhu X, Shi Q and Yang
H: Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy
by downregulating survivin. Arch Med Res. 41:162–169. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Church DN and Talbot DC: Survivin in solid
tumors: Rationale for development of inhibitors. Curr Oncol Rep.
14:120–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang H, Shao H, Yu C and Hou J: Mcl-1
downregulation by YM155 contributes to its synergistic anti-tumor
activities with ABT-263. Biochem Pharmacol. 82:1066–1072. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feng W, Yoshida A and Ueda T: YM155
induces caspase-8 dependent apoptosis through downregulation of
survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res
Commun. 435:52–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thomas LW, Lam C and Edwards SW: Mcl-1;
the molecular regulation of protein function. FEBS Lett.
584:2981–2989. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Na YS, Yang SJ, Kim SM, Jung KA, Moon JH,
Shin JS, Yoon DH, Hong YS, Ryu MH, Lee JL, et al: YM155 induces
EGFR suppression in pancreatic cancer cells. PLoS One.
7:e386252012. View Article : Google Scholar : PubMed/NCBI
|
